410 related articles for article (PubMed ID: 8676350)
1. Design, synthesis, and biological activities of cyclic lactam peptide analogues of dynorphine A(1-11)-NH2.
Lung FD; Collins N; Stropova D; Davis P; Yamamura HI; Porreca F; Hruby VJ
J Med Chem; 1996 Mar; 39(5):1136-41. PubMed ID: 8676350
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the "address" sequence.
Arttamangkul S; Ishmael JE; Murray TF; Grandy DK; DeLander GE; Kieffer BL; Aldrich JV
J Med Chem; 1997 Apr; 40(8):1211-8. PubMed ID: 9111295
[TBL] [Abstract][Full Text] [Related]
3. Development of highly potent and selective dynorphin A analogues as new medicines.
Lung FD; Chen CH; Liu JH
J Pept Res; 2005 Nov; 66(5):263-76. PubMed ID: 16218994
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and opioid activity of side-chain-to-side-chain cyclic dynorphin A-(1-11) amide analogues cyclized between positions 2 and 5. 1. Substitutions in position 3.
Vig BS; Murray TF; Aldrich JV
J Med Chem; 2004 Jan; 47(2):446-55. PubMed ID: 14711314
[TBL] [Abstract][Full Text] [Related]
5. Prediction of the conformational requirements for binding to the kappa-opioid receptor and its subtypes. I. Novel alpha-helical cyclic peptides and their role in receptor selectivity.
Collins N; Hruby VJ
Biopolymers; 1994 Sep; 34(9):1231-41. PubMed ID: 7948735
[TBL] [Abstract][Full Text] [Related]
6. Effects of modifications of residues in position 3 of dynorphin A(1-11)-NH2 on kappa receptor selectivity and potency.
Lung FD; Meyer JP; Lou BS; Xiang L; Li G; Davis P; DeLeon IA; Yamamura HI; Porreca F; Hruby VJ
J Med Chem; 1996 Jun; 39(13):2456-60. PubMed ID: 8691442
[TBL] [Abstract][Full Text] [Related]
7. Effects of the substitution of Phe4 in the opioid peptide [D-Ala8]dynorphin A-(1-11)NH2.
Vig BS; Zheng MQ; Murray TF; Aldrich JV
J Med Chem; 2003 Sep; 46(19):4002-8. PubMed ID: 12954053
[TBL] [Abstract][Full Text] [Related]
8. [Nalpha-benzylTyr1,cyclo(D-Asp5,Dap8)]- dynorphin A-(1-11)NH2 cyclized in the "address" domain is a novel kappa-opioid receptor antagonist.
Patkar KA; Yan X; Murray TF; Aldrich JV
J Med Chem; 2005 Jul; 48(14):4500-3. PubMed ID: 15999987
[TBL] [Abstract][Full Text] [Related]
9. Biological and conformational examination of stereochemical modifications using the template melanotropin peptide, Ac-Nle-c[Asp-His-Phe-Arg-Trp-Ala-Lys]-NH2, on human melanocortin receptors.
Haskell-Luevano C; Nikiforovich G; Sharma SD; Yang YK; Dickinson C; Hruby VJ; Gantz I
J Med Chem; 1997 May; 40(11):1738-48. PubMed ID: 9171884
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological properties of highly potent cyclic dynorphin A analogues. Analogues cyclized between positions 5 and 11.
Meyer JP; Collins N; Lung FD; Davis P; Zalewska T; Porreca F; Yamamura HI; Hruby VJ
J Med Chem; 1994 Nov; 37(23):3910-7. PubMed ID: 7966152
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 1. Conformational constraint in the "message" sequence.
Arttamangkul S; Murray TF; DeLander GE; Aldrich JV
J Med Chem; 1995 Jun; 38(13):2410-7. PubMed ID: 7608905
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of dynorphin a analogues modified in the address sequence.
Schlechtingen G; DeHaven RN; Daubert JD; Cassel JA; Chung NN; Schiller PW; Taulane JP; Goodman M
J Med Chem; 2003 May; 46(11):2104-9. PubMed ID: 12747782
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution.
Choi H; Murray TF; DeLander GE; Schmidt WK; Aldrich JV
J Med Chem; 1997 Aug; 40(17):2733-9. PubMed ID: 9276018
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist.
Bennett MA; Murray TF; Aldrich JV
J Pept Res; 2005 Mar; 65(3):322-32. PubMed ID: 15787962
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs.
Kawasaki AM; Knapp RJ; Kramer TH; Walton A; Wire WS; Hashimoto S; Yamamura HI; Porreca F; Burks TF; Hruby VJ
J Med Chem; 1993 Mar; 36(6):750-7. PubMed ID: 8096246
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of highly potent and selective cyclic dynorphin A analogues.
Kawasaki AM; Knapp RJ; Kramer TH; Wire WS; Vasquez OS; Yamamura HI; Burks TF; Hruby VJ
J Med Chem; 1990 Jul; 33(7):1874-9. PubMed ID: 1972964
[TBL] [Abstract][Full Text] [Related]
17. Constrained corticotropin-releasing factor (CRF) agonists and antagonists with i-(i+3) Glu-Xaa-DXbb-Lys bridges.
Koerber SC; Gulyas J; Lahrichi SL; Corrigan A; Craig AG; Rivier C; Vale W; Rivier J
J Med Chem; 1998 Dec; 41(25):5002-11. PubMed ID: 9836618
[TBL] [Abstract][Full Text] [Related]
18. Dynorphin A analogs containing a conformationally constrained phenylalanine derivative in position 4: reversal of preferred stereochemistry for opioid receptor affinity and discrimination of kappa vs. delta receptors.
Aldrich JV; Zheng QI; Murray TF
Chirality; 2001; 13(3):125-9. PubMed ID: 11270320
[TBL] [Abstract][Full Text] [Related]
19. [2',6'-Dimethyltyrosine]dynorphin A(1-11)-NH2 analogues lacking an N-terminal amino group: potent and selective kappa opioid antagonists.
Lu Y; Nguyen TM; Weltrowska G; Berezowska I; Lemieux C; Chung NN; Schiller PW
J Med Chem; 2001 Sep; 44(19):3048-53. PubMed ID: 11543672
[TBL] [Abstract][Full Text] [Related]
20. Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile.
Tourwé D; Mannekens E; Diem TN; Verheyden P; Jaspers H; Tóth G; Péter A; Kertész I; Török G; Chung NN; Schiller PW
J Med Chem; 1998 Dec; 41(26):5167-76. PubMed ID: 9857087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
